Michael Brewster

1.5k total citations
29 papers, 1.1k citations indexed

About

Michael Brewster is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Brewster has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Brewster's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Michael Brewster is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Michael Brewster collaborates with scholars based in United Kingdom, Switzerland and United States. Michael Brewster's co-authors include María Cecilia Lanari, R.K. Tume, Aijun Yang, K M K Bottomley, Kevin L. Wilson, John Nixon, R D Christen, Ernesto Guarin, Antje‐Christine Walz and Christine McIntyre and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Pharmacology.

In The Last Decade

Michael Brewster

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Brewster United Kingdom 17 335 330 231 143 140 29 1.1k
Ruifeng Guo United States 14 217 0.6× 301 0.9× 641 2.8× 16 0.1× 103 0.7× 64 1.3k
Sibel Erdoğan Türkiye 15 63 0.2× 239 0.7× 253 1.1× 26 0.2× 79 0.6× 42 774
Greta Gandolfi Italy 19 104 0.3× 337 1.0× 594 2.6× 39 0.3× 228 1.6× 30 1.3k
Shiguang Yu United States 20 48 0.1× 126 0.4× 260 1.1× 52 0.4× 102 0.7× 51 1.0k
J. C. Bartley United States 20 60 0.2× 303 0.9× 574 2.5× 79 0.6× 222 1.6× 37 1.1k
A. Zimber Israel 18 106 0.3× 461 1.4× 701 3.0× 20 0.1× 220 1.6× 52 1.4k
Annemieke de Vries Netherlands 26 56 0.2× 918 2.8× 1.2k 5.3× 47 0.3× 506 3.6× 60 2.1k
Nagathihalli S. Nagaraj United States 17 61 0.2× 306 0.9× 528 2.3× 21 0.1× 243 1.7× 26 972
Hidematsu Hirai Japan 18 47 0.1× 109 0.3× 387 1.7× 135 0.9× 63 0.5× 70 1.0k
W.A. Thomas United States 26 158 0.5× 63 0.2× 475 2.1× 68 0.5× 152 1.1× 88 1.9k

Countries citing papers authored by Michael Brewster

Since Specialization
Citations

This map shows the geographic impact of Michael Brewster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Brewster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Brewster more than expected).

Fields of papers citing papers by Michael Brewster

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Brewster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Brewster. The network helps show where Michael Brewster may publish in the future.

Co-authorship network of co-authors of Michael Brewster

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Brewster. A scholar is included among the top collaborators of Michael Brewster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Brewster. Michael Brewster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gibiansky, Ekaterina, Leonid Gibiansky, Nicolas Frey, et al.. (2019). Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study. British Journal of Clinical Pharmacology. 85(9). 1935–1945. 7 indexed citations
2.
Qin, Yan, Jun Zhu, Yuqin Song, et al.. (2017). Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas. British Journal of Clinical Pharmacology. 83(7). 1446–1456. 6 indexed citations
3.
Davies, Andrew, Francesco Merli, Biljana Mihaljević, et al.. (2017). Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. The Lancet Haematology. 4(6). e272–e282. 83 indexed citations
4.
5.
Dakhil, Shaker R., Róbert Hermann, Marshall T. Schreeder, et al.. (2014). Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leukemia & lymphoma. 55(10). 2335–2340. 19 indexed citations
6.
Garg, Amit, Jing Li, Emma Clark, et al.. (2013). Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemotherapy and Pharmacology. 72(5). 1133–1141. 19 indexed citations
7.
8.
Felip, Enriqueta, Malcolm Ranson, S. Cedrés, et al.. (2010). Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7540–7540. 1 indexed citations
9.
Felip, Enriqueta, Malcolm Ranson, S. Cedrés, et al.. (2008). A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients. Journal of Clinical Oncology. 26(15_suppl). 19134–19134. 3 indexed citations
10.
Albanell, Joan, Clara Montagut, Begoña Mellado, et al.. (2008). A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(9). 2726–2731. 30 indexed citations
11.
Yang, Aijun, Michael Brewster, María Cecilia Lanari, & R.K. Tume. (2003). OXIDATION OF LIPIDS IN SARCOPLASMIC RETICULUM OF MUSCLES FROM PASTURE‐ AND GRAIN‐FED CATTLE WITH OR WITHOUT VITAMIN E SUPPLEMENTATION. Journal of Food Lipids. 10(3). 179–191. 3 indexed citations
12.
Yang, Aijun, María Cecilia Lanari, Michael Brewster, & R.K. Tume. (2002). Lipid stability and meat colour of beef from pasture- and grain-fed cattle with or without vitamin E supplement. Meat Science. 60(1). 41–50. 179 indexed citations
13.
Yang, Aijun, Michael Brewster, María Cecilia Lanari, & R.K. Tume. (2002). Effect of vitamin E supplementation on α-tocopherol and β-carotene concentrations in tissues from pasture- and grain-fed cattle. Meat Science. 60(1). 35–40. 136 indexed citations
14.
Lanari, María Cecilia, Michael Brewster, Aijun Yang, & R.K. Tume. (2002). Pasture and Grain Finishing Affect the Color Stability of Beef. Journal of Food Science. 67(7). 2467–2473. 36 indexed citations
15.
Brewster, Michael, et al.. (1998). Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis & Rheumatism. 41(9). 1639–1644. 66 indexed citations
16.
Lewis, E. J., Joshua D. Bishop, K M K Bottomley, et al.. (1997). Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. British Journal of Pharmacology. 121(3). 540–546. 100 indexed citations
17.
Greenhouse, John P., et al.. (1993). Geophysics and solvents: The Borden experiment. The Leading Edge. 12(4). 261–267. 46 indexed citations
18.
Gater, Paul R., et al.. (1993). The inhibitory effects of Ro 31-6930 and BRL 38227 on cholinergically-mediated bronchoconstriction in the guinea-pig. European Journal of Pharmacology. 238(1). 59–64. 2 indexed citations
19.
Natoff, Ian L., John Nixon, Robert J. Francis, et al.. (1985). Biological Properties of the Angiotensin-Converting Enzyme Inhibitor Cilazapril. Journal of Cardiovascular Pharmacology. 7(3). 569–580. 64 indexed citations
20.
Natoff, Ian L., Michael Brewster, & Anita T. Patel. (1981). Method for measuring the duration of inhibition of angiotensin I-converting enzyme in vivo. Journal of Pharmacological Methods. 5(4). 305–312. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruifeng Guo Breakdown of academic impact, for papers by Sibel Erdoğan Breakdown of academic impact, for papers by Greta Gandolfi Breakdown of academic impact, for papers by Shiguang Yu Breakdown of academic impact, for papers by J. C. Bartley Breakdown of academic impact, for papers by A. Zimber Breakdown of academic impact, for papers by Annemieke de Vries Breakdown of academic impact, for papers by Nagathihalli S. Nagaraj Breakdown of academic impact, for papers by Hidematsu Hirai Breakdown of academic impact, for papers by W.A. Thomas
Rankless by CCL
2026